Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis

BACKGROUND: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common adult leukemia, accounting for ≈ 37% of all leukemias in the United States. Limited real-word evidence is available on the outcomes of ibrutinib use among previously untreated patients in the U.S. Vetera...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qing, Borra, Sujana, Li, Jieni, Wang, Li, Shrestha, Sulena, Sundaram, Murali, Janjan, Nora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391290/
https://www.ncbi.nlm.nih.gov/pubmed/32880204
http://dx.doi.org/10.18553/jmcp.2020.20095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391290/
https://www.ncbi.nlm.nih.gov/pubmed/32880204
http://dx.doi.org/10.18553/jmcp.2020.20095

Ejemplares similares